Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update
- DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended.
- 05/15/2025
|
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
- DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares (“ADSs”) for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days.
- 03/14/2025
|
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
- DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan.
- 03/13/2025
|
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology
- DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors.
- 02/28/2025
|
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
- Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029
- 02/06/2025
|
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
- Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029
- 01/28/2025
|
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
- DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
- 12/24/2024
|
Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV
- DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.
- 12/18/2024
|
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
- Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call.
- 11/15/2024
|
Trinity Biotech Announces Q3 2024 Financial Results
- Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement.
- 11/15/2024
|
Trinity Biotech to Announce Q3 2024 Financial Results
- Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
- 11/14/2024
|
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
- DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”).
- 11/07/2024
|
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
- DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus' groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.
- 10/25/2024
|
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
- DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech's strategic expansion into the oncology diagnostics market.
- 10/25/2024
|
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
- TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
- 10/08/2024
|
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
- DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.
- 10/07/2024
|
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
- TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
- 09/25/2024
|
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
- -Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
- 09/24/2024
|
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
- DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on its development and global launch plans for its next generation Continuous Glucose Monitoring (“CGM”) technology. CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring.
- 09/18/2024
|
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
- TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
- 09/10/2024
|
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
- DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of Trinity Biotech's glucose biosensor. Trinity Biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (CGM) technology.
- 09/09/2024
|
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
- DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products.
- 09/03/2024
|
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
- DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV. As a result of this strong demand and the successful scaling of production capacity, the Company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from $8 million previously.
- 08/26/2024
|
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
- DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets.
- 08/20/2024
|
Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Simon Dunne - Chief Accounting Officer Conference Call Participants Jim Sidoti - Sidoti & Company Andrew Mei - Private Investor Operator Welcome to the Trinity Biotech Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 08/16/2024
|
Trinity Biotech Announces Q2 2024 Financial Results
- -Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business-
- 08/14/2024
|
Trinity Biotech to Announce Q2 2024 Financial Results
- Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET
- 08/13/2024
|
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
- DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to demonstrate compliance with a continued listing requirement of The Nasdaq Global Select Market.
- 08/06/2024
|
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
- -Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth-
- 08/02/2024
|
Trinity Biotech Announces Appointment of A New CFO
- DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer (“CFO”). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024.
- 07/09/2024
|
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
- DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“CGM”) solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now received regulatory approval to conduct its initial European pre-pivotal trial that will inform the larger pivotal trial that will be required for product registration and launch.
- 06/24/2024
|
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
- DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024.
- 06/10/2024
|
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
- DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM biosensor technology and artificial intelligence (“AI”) driven health & wellness analytics platform, as well as providing additional visibility on the international commercialisation of these solutions.
- 06/03/2024
|
Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 05/23/2024
|
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
- -Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-
- 05/23/2024
|
Trinity Biotech plc to Announce Q1 2024 Financial Results
- DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date: Thursday, May 23, 2024 Time: 8:30 AM ET United States: 1-877-407-0784 International: 1- 201-689-8560 Conference ID: Webcast:Call me™: 13746798 webcast link https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors.
- 05/21/2024
|
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
- DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company's recently acquired continuous glucose monitor (CGM) biosensor technology.
- 05/16/2024
|
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
- DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.
- 05/13/2024
|
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company's recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market.
- 05/08/2024
|
Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q4 2023 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Eric Ribner - Investor Relations Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Operator Greetings! Welcome to the Trinity Biotech's Fourth Quarter and Full Year 2023 Earnings Conference Call.
- 04/04/2024
|
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
- DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
- 04/04/2024
|
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
- DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET. Conference Call Dial-In & Webcast Information Date: Thursday, April 4, 2024 Time: 8:00 AM ET United States: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13745604 Call me™: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 Webcast Click here for webcast About Trinity Biotech Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
- 03/28/2024
|
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.
- 03/08/2024
|
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
- DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 23, 2024 (U.S. Eastern Time) (the “Effective Date”).
- 02/15/2024
|
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
- DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing four (4) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.
- 02/13/2024
|
Trinity Biotech to Present at Emerging Growth Conference
- DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Please see the presentation information below.
- 02/08/2024
|
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
- DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
- 02/07/2024
|
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
- Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
- 02/02/2024
|
Trinity Biotech plc (TRIB) Acquisition of the CGM Assets of Waveform Technologies and Q3 2023 Earnings Call (Transcript)
- Trinity Biotech plc (TRIB) Acquisition of the CGM Assets of Waveform Technologies and Q3 2023 Earnings Call (Transcript)
- 01/31/2024
|
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
- DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company's results for the quarter ended September 30, 2023. Business Updates and Strategic Priorities In December 2023, the Company announced the promotion of John Gillard from CFO to CEO and the promotion of Des Fitzgerald to the role of Interim CFO.
- 01/31/2024
|
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
- DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India. This Letter of Intent is related to the Company's recently announced acquisition of the CGM assets of Waveform Technologies, Inc.
- 01/31/2024
|
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
- -Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management
- 01/31/2024
|
Trinity Biotech plc to Host Investor Call
- Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET
- 01/30/2024
|
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
- DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV.
- 12/27/2023
|
Trinity Biotech Announces Management Changes
- John Gillard Named Chief Executive Officer Des Fitzgerald Named Interim Chief Financial Officer DUBLIN, Ireland, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the promotion of John Gillard, our Chief Financial Officer, to President and Chief Executive Officer, effective immediately. Des Fitzgerald, who has served as Director of Corporate Development of Trinity Biotech since October 2022, has been promoted to Interim Chief Financial Officer, succeeding Mr.
- 12/18/2023
|
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
- DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on November 21, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the minimum market value of publicly held shares ("MVPHS") requirement set forth in the Nasdaq Listing Rules.
- 11/28/2023
|
Trinity Biotech plc (TRIB) Q2 2023 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q2 2023 Earnings Call Transcript October 3, 2023 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, Investor Relations Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Good day, and welcome to Trinity Biotech Announces Second Quarter Financial Results. All participants will be in listen-only mode.
- 10/03/2023
|
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
- DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.
- 09/27/2023
|
Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
- DUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023. The Company has scheduled a conference call for that same day, July 6, 2023 at 11:00am ET (16:00pm BST) to discuss the results of the quarter.
- 07/03/2023
|
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
- Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN Conference Call Scheduled for March 23, 2023 at 10:00 am EASTERN
- 03/16/2023
|
Trinity Biotech plc (TRIB) Q3 2022 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q3 2022 Earnings Conference Call December 15, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Fund Operator Good day. And welcome to the Trinity Biotech Third Quarter Financial Results Conference Call.
- 12/15/2022
|
Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results
- Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN Conference Call Scheduled for December 15, 2022 at 11:00 am EASTERN
- 12/09/2022
|
Trinity Biotech plc (TRIB) Q2 2022 Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q2 2022 Results Conference Call November 3, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Aris Kekedjian - Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Operator Good day, and welcome to the Trinity Biotech Second Quarter Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 11/05/2022
|
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial Results
- Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN Conference Call Scheduled for November 3, 2022 at 11:00 am EASTERN
- 11/01/2022
|
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2022 Results - Earnings Call Transcript
- Trinity Biotech plc (NASDAQ:TRIB ) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan O'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode.
- 06/30/2022
|
Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
- Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN
- 06/29/2022
|
Trinity Biotech Stock Surges After $45M Capital Infusion From Korea-Based Firm
- Trinity Biotech plc (NASDAQ: TRIB) announced a $45 million investment and partnership with MiCo Ltd, a KOSDAQ-listed and Korea-based company. MiCo is engaged in the biomedical business through its affiliate MiCo BioMed and provides cutting-edge technology-driven solutions in.
- 04/11/2022
|
Trinity Biotech shares jump 6% premarket after WHO approves is rapid test for HIV
- Dublin-based Trinity Biotech Plc shares TRIB, -4.24% jumped 6% premarket Monday, after the company said it has received approval from the World Health Organization for its HIV screening product, TrinScreen. The company's Uni-Gold HIV product has served as the main confirmatory test for the detection of HIV in Africa for many years.
- 02/14/2022
|
Trinity Biotech Enters Into $81M Loan Facility To Refinance Existing Debt
- Trinity Biotech plc (NASDAQ: TRIB) has entered into an $81.25 million loan facility to refinance the existing $99.9 million of exchangeable senior notes. The Company entered into an $81.25 million senior secured term loan credit facility with Perceptive Advisors.
- 12/16/2021
|
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2021 Results - Earnings Call Transcript
- Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2021 Results - Earnings Call Transcript
- 09/09/2021
|
TRIB Stock: Why It Increased Today
- The stock price of Trinity Biotech plc (NASDAQ: TRIB) increased today. This is why it happened.
- 09/09/2021
|
Trinity Biotech Announces Results for Q2, 2021
- DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021.
- 09/09/2021
|
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2021 Financial Results
- Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN
- 08/31/2021
|
Trinity Biotech Provides A Business Development Update For Q2 2021
- DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
- 07/16/2021
|
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2021 Results - Earnings Call Transcript
- Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2021 Results - Earnings Call Transcript
- 05/25/2021
|
Trinity Biotech Announces Results for Q1, 2021
- DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021.
- 05/25/2021
|
Top Penny Stocks For Your May Watchlist? Check These 5 Out
- Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?
- 05/13/2021
|
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q4 2020 Results - Earnings Call Transcript
- Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Trinity Biotech Announces Quarter 4 and Fiscal Year 2020 Financial Results
- DUBLIN, Ireland, March 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2020 and fiscal year 2020.
- 03/25/2021
|
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2020 Financial Results
- Conference Call Scheduled for March 25, 2021 at 11:00 am EASTERN Conference Call Scheduled for March 25, 2021 at 11:00 am EASTERN
- 03/23/2021
|
Trinity Biotech Announces CE Mark of its Covid-19 IgG ELISA Antibody Test
- DUBLIN, Ireland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia™ SARS-CoV-2 IgG ELISA.
- 01/05/2021
|
Is Trinity Biotech plc (TRIB) A Good Stock To Buy?
- Is Trinity Biotech plc (NASDAQ:TRIB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
- 11/27/2020
|
Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q3 2020 Results - Earnings Call Transcript
- Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q3 2020 Results - Earnings Call Transcript
- 11/17/2020
|
Trinity Biotech Announces Results for Q3, 2020
- DUBLIN, Ireland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2020.
- 11/17/2020
|
Trinity Biotech plc to Announce Third Quarter 2020 Financial Results
- Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN
- 10/29/2020
|
